Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab

• Published in: Journal of Alzheimer's disease Vol. 34; no. 4; p. 897
• Main Authors: Lachno, D Richard, Evert, Barbara A, Vanderstichele, Hugo, Robertson, Michael, Demattos, Ronald B, Konrad, Robert J, Talbot, Jayne A, Racke, Margaret M, Dean, Robert A
• Format: Journal Article
• Language: English
• Published: Netherlands 01.01.2013
• Subjects: Alzheimer Disease - blood; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - drug therapy; Amyloid beta-Peptides - blood; Amyloid beta-Peptides - cerebrospinal fluid; Amyloid beta-Peptides - immunology; Antibodies, Monoclonal, Humanized - therapeutic use; Antipsychotic Agents - therapeutic use; Biotinylation; Calibration; Enzyme-Linked Immunosorbent Assay; Female; Humans; Linear Models; Male; Peptide Fragments - blood; Peptide Fragments - cerebrospinal fluid; Reference Values; Reproducibility of Results; Time Factors

The aim of this study was to validate new assays for measurement of amyloid-β (Aβ) peptides in cerebrospinal fluid (CSF) and plasma specimens in clinical studies of solanezumab according to current regulatory recommendations. Four assays based on the INNOTEST® β-AMYLOID(1-42) and prototype INNOTEST...